PO-CHIN LIANGCh’ang H.-J.CHIUN HSUChen L.-T.TIFFANY TING-FANG SHIHLiu T.W.2020-08-112020-08-1120151936-0533https://scholars.lib.ntu.edu.tw/handle/123456789/511369Background: To correlate between signal parameters using dynamic contrast-enhanced magnetic resonance imaging (DCEMRI) and outcomes of hepatocellular carcinoma (HCC) receiving radiotherapy with or without concomitant thalidomide. Methods: DCEMRI was performed in advanced HCC patients undergoing radiotherapy with or without concomitant thalidomide. Initial first-pass enhancement slopes (slope) and peak enhancement ratios (peak) were measured over an operator-defined region of interest over tumor and non-tumor liver parenchyma. The perfusion parameters were correlated with clinical outcomes. The study was registered with ClinicalTrials.gov. (identifier NCT00155272). Results: Forty-three patients were evaluable. There were 18 partial responses (PRs), 5 minimal responses (MRs), 17 stable diseases (SDs), and 3 progressive diseases (PDs). Baseline perfusion parameters as well as slope at 14?days of radiotherapy were higher in patients with PR or MR compared to SD or PD (0.81?±?0.29 vs. 0.49?±?0.34, p?<?0.01; 0.39?±?0.15 vs. 0.28?±?0.16, p?=?0.02; 0.97?±?0.38 vs. 0.46?±?0.26, p?<?0.01; respectively). Multivariate analysis revealed perfusion parameters over liver parenchyma, but not over tumor, and independently predicted progression-free and overall survival (182?±?33 vs. 105?±?26?days, p?=?0.01; 397?±?111 vs. 233?±?19?days, p?=?0.001 respectively). For 22 patients receiving concomitant thalidomide, the perfusion parameters were not significantly different from those receiving radiotherapy alone. Conclusions: Signal parameters of DCEMRI over tumor and liver parenchyma correlated with tumor response and survival, respectively, in HCC patients receiving radiotherapy. ? 2014, Asian Pacific Association for the Study of the Liver.[SDGs]SDG3angiogenesis inhibitor; contrast medium; gadodiamide; gadolinium pentetate; thalidomide; aged; Carcinoma, Hepatocellular; clinical trial; disease free survival; female; human; Liver Neoplasms; male; multimodality cancer therapy; nuclear magnetic resonance imaging; phase 2 clinical trial; procedures; signal processing; survival rate; treatment outcome; Aged; Angiogenesis Inhibitors; Carcinoma, Hepatocellular; Combined Modality Therapy; Contrast Media; Disease-Free Survival; Female; Gadolinium DTPA; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Signal Processing, Computer-Assisted; Survival Rate; Thalidomide; Treatment Outcomejournal article10.1007/s12072-014-9557-1257881782-s2.0-84938849309